Report
BioNTech SE : Omicron-specific variant of coronavirus vaccine leads to up to 19.6x increase in neutralising antibody titers
>Monovalent vaccine results in strong boost of neutralising antibodies - Pfizer and BioNTech published clinical data on two different adapted coronavirus vaccine candidates, on a Omicron (BA.1)-adapted monovalent vaccine candidate and a bivalent vaccine candidate (original vaccine + Omicron-adapted version) having been applied at two different doses (30 µg and 60 µg). The monovalent vaccine results in a 13.5x and 19.6x increase in geometric titers of neutralising a...
Underlying
BioNTech SE
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Oliver Metzger
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.